Yanxiao Wang

Yanxiao Wang

Auto-generated profile, based on publicly available information

Yanxiao Wang

National Institute of Biological Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Cell Reports
Verified
Journal Article
Open access
YCYaxiong Cui
Yaxiong Cui
YWYanxiao Wang
Yanxiao Wang
XSXiaopeng Song
Xiaopeng Song
HNHuimin Ning
Huimin Ning
YZYizhe Zhang
Yizhe Zhang
XYXiao Yang
Xiao Yang
The low level of transcytosis is a unique feature of cerebrovascular endothelial cells (ECs), ensuring restrictive blood-brain barrier (BBB) permeability. Major facilitator superfamily domain-containing 2a (MFSD2A) is a key regulator of the BBB function by suppressing caveolae-mediated transcytosis. However, the mechanisms regulating MFSD2A at the BBB have been barely explored. Here, we show that cerebrovascular EC-specific deletion of Pten (phosphatase and tensin homolog) results in a dramatic increase in vesicular transcytosis by the reduction of MFSD2A, leading to increased transcellular permeability of the BBB. Mechanistically, AKT signaling inhibits E3 ubiquitin ligase NEDD4-2-mediated MFSD2A degradation. Consistently, cerebrovascular Nedd4-2 overexpression decreases MFSD2A levels, increases transcytosis, and impairs BBB permeability, recapitulating the phenotypes of Pten-deficient mice. Furthermore, Akt deletion decreases phosphorylated NEDD4-2 levels, restores MFSD2A levels, and normalizes BBB permeability in Pten-mutant mice. Altogether, our work reveals the essential physiological function of the PTEN/AKT/NEDD4-2/MFSD2A axis in the regulation of BBB permeability.

11 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
XTXiaohong Tan
Xiaohong Tan
LTLu Tong
Lu Tong
LLLin Li
Lin Li
JXJinjin Xu
Jinjin Xu
SXShaofang Xie
Shaofang Xie
HLHenry (Xiaotao) James Li
Henry (Xiaotao) James Li
SMAD4 is mutated in human lung cancer, but the underlying mechanism by which Smad4 loss-of-function (LOF) accelerates lung cancer metastasis is yet to be elucidated. Here, we generate a highly aggressive lung cancer mouse model bearing conditional Kras G12D , p53 fl/fl LOF and Smad4 fl/fl LOF mutations (SPK), showing a much higher incidence of tumor metastases than the Kras G12D , p53 fl/fl (PK) mice. Molecularly, PAK3 is identified as a downstream effector of Smad4, mediating metastatic signal transduction via the PAK3-JNK-Jun pathway. Upregulation of PAK3 by Smad4 LOF in SPK mice is achieved by attenuating Smad4-dependent transcription of miR-495 and miR-543. These microRNAs (miRNAs) directly bind to the PAK3 3′UTR for blockade of PAK3 production, ultimately regulating lung cancer metastasis. An inverse correlation between Smad4 and PAK3 pathway components is observed in human lung cancer. Our study highlights the Smad4-PAK3 regulation as a point of potential therapy in metastatic lung cancer.

26 September 2023 in Cell Discovery
Verified
Journal Article
Open access
PDF file
YWYanxiao Wang
Yanxiao Wang
EBEnnan Bin
Ennan Bin
JYJie Yuan
Jie Yuan
MHMan Huang
Man Huang
JCJingyu Chen
Jingyu Chen
NTNan Tang
Nan Tang